There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vir Biotechnology (VIR – Research Report), Blueprint Medicines (BPMC – Research Report) and Caribou Biosciences (CRBU – Research Report) with bullish sentiments.
Vir Biotechnology (VIR)
In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Vir Biotechnology, with a price target of $200.00. The company’s shares closed last Monday at $40.48, close to its 52-week low of $25.31.
According to TipRanks.com, Trucchio is ranked 0 out of 5 stars with an average return of
Vir Biotechnology has an analyst consensus of Moderate Buy, with a price target consensus of $81.83, implying a 109.0% upside from current levels. In a report issued on November 17, Needham also reiterated a Buy rating on the stock with a $80.00 price target.
See the top stocks recommended by analysts >>
Blueprint Medicines (BPMC)
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Blueprint Medicines, with a price target of $135.00. The company’s shares closed last Monday at $98.28.
According to TipRanks.com, Fein is a 4-star analyst with an average return of
Blueprint Medicines has an analyst consensus of Moderate Buy, with a price target consensus of $124.63, a 21.6% upside from current levels. In a report released yesterday, Wedbush also maintained a Buy rating on the stock with a $139.00 price target.
Caribou Biosciences (CRBU)
In a report released today, Robert Burns from H.C. Wainwright initiated coverage with a Buy rating on Caribou Biosciences and a price target of $28.00. The company’s shares closed last Monday at $17.05, close to its 52-week low of $15.00.
According to TipRanks.com, Burns ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Caribou Biosciences is a Strong Buy with an average price target of $29.00, representing a 60.2% upside. In a report issued on November 15, Citigroup also upgraded the stock to Buy with a $27.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VIR:
- Co-Diagnostics (CODX) Receives a Buy from H.C. Wainwright
- Analyst Explains Why They Upgraded Their Rating on Applied DNA Sciences (APDN)
- Artelo Biosciences (ARTL) Receives a Buy from H.C. Wainwright
- H.C. Wainwright Reiterates Their Buy Rating on Western Copper (WRN)
- Fury Gold Mines (FURY) Receives a Buy from H.C. Wainwright
